Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature.
Publication Title
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology
Document Type
Article
Publication Date
3-1-2024
Keywords
Humans; Hepatoblastoma; Prospective Studies; Risk Factors; Incidence; Neoplasms, Second Primary; Hematologic Neoplasms; Liver Neoplasms; washington; spokane; pshmc
Abstract
Treatment intensification has improved survival in patients with hepatoblastoma (HB); however, these treatments are associated with an increased risk of late effects, including second malignant neoplasms (SMNs). Data is limited regarding SMNs following HB treatment. Cases of SMNs following treatment for HB reported in the literature and from personal communication were analyzed to further assess this late effect. Thirty-eight patients were identified. The median age at diagnosis of HB was 16 months (range
Clinical Institute
Women & Children
Specialty/Research Institute
Pediatrics
Specialty/Research Institute
Hematology
Specialty/Research Institute
Oncology
DOI
10.1097/MPH.0000000000002824
